The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).
 
Sanjal Desai
No Relationships to Disclose
 
Raphael Mwangi
No Relationships to Disclose
 
Rebecca L. King
No Relationships to Disclose
 
Matthew J. Maurer
Consulting or Advisory Role - Kite, a Gilead company; MorphoSys; Pfizer
Research Funding - Celgene (Inst); Genentech (Inst); Morphosys (Inst); NanoString Technologies (Inst)
 
James Robert Cerhan
Consulting or Advisory Role - Janssen; Janssen
Research Funding - Celgene (Inst); Genentech (Inst); NanoString Technologies (Inst)
 
Andew L. Feldman
No Relationships to Disclose
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Eric Mou
No Relationships to Disclose
 
Umar Farooq
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Carrie A. Thompson
No Relationships to Disclose
 
Yucai Wang
Consulting or Advisory Role - Loxo (Inst)
Research Funding - Genentech (Inst); Incyte (Inst); InnoCare (Inst); Novartis (Inst)
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); ADC Therapeutics; Celgene (Inst); Cellectar; Epizyme; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group; Genentech (Inst); Kite/Gilead; MorphoSys (Inst); Selvita
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)